With more and more Americans facing economic hardships as a result of the COVID-19 pandemic, Astellas has implemented changes to its patient assistance programs as part of the company’s ongoing commitment to ensuring that patients have access to our products. Astellas Pharma Support SolutionsSM offers support to patients needing access and reimbursement assistance.
Astellas has made the patient assistance program application and verification process easily accessible for patients who have lost their jobs or insurance coverage as a result of COVID-19, and has increased customer service capacity in light of the influx of patients requiring assistance. Important resources regarding patient healthcare coverage and financial assistance options are also available.
“We recognize the impact that the COVID-19 pandemic is having on patients and healthcare systems and want to ensure we do all we can to meet patient needs,” said Percival Barretto-Ko, president of Astellas U.S. “During these challenging times, many people are experiencing financial stresses and are worried about how to pay their bills. They should not have to worry about how to get their prescription medications. We will continue to do all that we can to help ensure that patients have access to – and can afford – their critical Astellas medicines.”
Some of the products patients can access support for include:
AmBisome® (amphotericin B) liposome for injection;
Cresemba® (isavuconazonium sulfate) 372 mg for injection; 186 mg capsules;
Lexiscan® (regadenoson) injection 0.4 mg/5 mL;
Mycamine® (micafungin for injection) for intravenous use;
Myrbetriq® (mirabegron) extended-release tablets 25 mg, 50 mg;
Xospata® (gilteritinib) 40 mg tablets; Please click here for Xospata full prescribing information, including boxed warning;
Xtandi® (enzalutamide) 40 mg capsules
Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.